Biohaven .(US:BHVN) GlobeNewswire News Roomยท2025-07-25 15:50Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Biohaven Ltd. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's drug candidates and their regulatory prospects [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Biohaven between March 24, 2023, and May 14, 2025, to contact them for discussing legal options [1]. - A federal securities class action has been filed against Biohaven, with a deadline of September 12, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Biohaven - The complaint alleges that Biohaven and its executives made false and misleading statements regarding the regulatory prospects of the drug troriluzole for treating spinocerebellar ataxia (SCA) and the efficacy of BHV-7000 for bipolar disorder [5]. - The allegations suggest that the overstated claims about these drugs' prospects could significantly negatively impact Biohaven's business and financial condition once revealed [5]. Group 3: Stock Price Impact - Following a press release on May 14, 2025, regarding the extension of the PDUFA date for the troriluzole NDA, Biohaven's stock price fell by $3.84 per share, or 19.53%, closing at $15.82 per share on May 15, 2025 [6].